{"id":1284,"date":"2013-09-01T12:07:00","date_gmt":"2013-09-01T10:07:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/europaeische-arzneimittel-agentur-ema-kein-erhoehtes-risiko-fuer-pankreas-neoplasien-durch-inkretinmimetika"},"modified":"2013-09-01T12:07:00","modified_gmt":"2013-09-01T10:07:00","slug":"europaeische-arzneimittel-agentur-ema-kein-erhoehtes-risiko-fuer-pankreas-neoplasien-durch-inkretinmimetika","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/2013\/europaeische-arzneimittel-agentur-ema-kein-erhoehtes-risiko-fuer-pankreas-neoplasien-durch-inkretinmimetika","title":{"rendered":"Europ\u00e4ische Arzneimittel-Agentur (EMA): Kein erh\u00f6htes Risiko f\u00fcr Pankreas-Neoplasien durch Inkretinmimetika"},"content":{"rendered":"<p>Wir haben in letzter Zeit wiederholt, zuletzt im Mai 2013 (1), \u00fcber Warnsignale hinsichtlich Pankreaserkrankungen (Pankreatitis, Neoplasien) unter Anwendung von Inkretinmimetika (GLP1-Analoga, Dipeptidyl-Peptidase-Typ-IV-Hemmer) berichtet. Das &#8222;Committee for Medicinal Products for Human Use&#8220; (CHMP) hat jetzt laut einer Mitteilung der EMA vom 26. Juli 2013 (2) eine \u00dcberpr\u00fcfung dieser Signale beendet. Es kam zu dem Schluss, [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Wir haben in letzter Zeit wiederholt, zuletzt im Mai 2013 (1), \u00fcber Warnsignale hinsichtlich Pankreaserkrankungen (Pankreatitis, Neoplasien) unter Anwendung von Inkretinmimetika (GLP1-Analoga, Dipeptidyl-Peptidase-Typ-IV-Hemmer) berichtet. Das &#8222;Committee for Medicinal Products for Human Use&#8220; (CHMP) hat jetzt laut einer Mitteilung der EMA vom 26. Juli 2013 (2) eine \u00dcberpr\u00fcfung dieser Signale beendet. Es kam zu dem Schluss, [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[155,1284,1283,2822,1310,1309,222,2291,2823,277,2824,2598,1308,1441,1442],"class_list":["post-1284","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-diabetes-mellitus-typ-2","tag-ema","tag-europaeische-arzneimittel-agentur","tag-exenatid","tag-gliptine","tag-inkretinmimetika","tag-karzinome","tag-linagliptin","tag-liraglutid","tag-pankreaskarzinom","tag-pankreasneoplasien","tag-pankreatitis","tag-saxagliptin","tag-sitagliptin","tag-vildagliptin"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1284","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=1284"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/1284\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=1284"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=1284"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=1284"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}